product description The efficacy of the treatment of advanced renal cell carcinoma Adverse reactions
ChemicalBook > CAS DataBase List > Pazopanib

Pazopanib

product description The efficacy of the treatment of advanced renal cell carcinoma Adverse reactions
Product Name
Pazopanib
CAS No.
444731-52-6
Chemical Name
Pazopanib
Synonyms
Votrient;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;5-[[4-[(2,3-DiMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-benzenesulfonaMide;CS-1857;Pazopanib;Pazopanibr;Pezopanil Hcl;Pazopanib base;Pazopanib, >=99%;GW786034; VOTRIENT
CBNumber
CB91562449
Molecular Formula
C21H23N7O2S
Formula Weight
437.52
MOL File
444731-52-6.mol
More
Less

Pazopanib Property

Melting point:
285-289°C (dec.)
Boiling point:
728.8±70.0 °C(Predicted)
Density 
1.40
Flash point:
359℃
storage temp. 
Refrigerator
solubility 
Aqueous Acid (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated)
pka
10.19±0.60(Predicted)
form 
Yellow powder.
color 
White to Beige
More
Less

Safety

Risk Statements 
43-62/63
Safety Statements 
36/37/39-28B
HS Code 
29350090
Hazardous Substances Data
444731-52-6(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H373May cause damage to organs through prolonged or repeated exposure

H411Toxic to aquatic life with long lasting effects

Precautionary statements

P202Do not handle until all safety precautions have been read and understood.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P273Avoid release to the environment.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P308+P313IF exposed or concerned: Get medical advice/attention.

P391Collect spillage. Hazardous to the aquatic environment

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
CDS023580
Product name
Pazopanib
Packaging
25MG
Price
$84.9
Updated
2024/03/01
Sigma-Aldrich
Product number
SML3104
Product name
Pazopanib
Purity
≥98% (HPLC)
Packaging
10MG
Price
$81.3
Updated
2022/05/15
Sigma-Aldrich
Product number
SML3104
Product name
Pazopanib
Purity
≥98% (HPLC)
Packaging
50MG
Price
$328
Updated
2022/05/15
Cayman Chemical
Product number
12097
Product name
Pazopanib
Purity
≥98%
Packaging
10mg
Price
$29
Updated
2024/03/01
Cayman Chemical
Product number
12097
Product name
Pazopanib
Purity
≥98%
Packaging
25mg
Price
$65
Updated
2024/03/01
More
Less

Pazopanib Chemical Properties,Usage,Production

product description

Pazopanib(444731-52-6) is researched and developed by a GlaxoSmithKline ,it is a novel oral vascular generation inhibitor which may interfere stubborn tumor survival and new blood vessels generation growth needed .Targeting vascular endothelial growth factor receptor (VEGFR),it works by inhibiting angiogenesis of tumor blood supply.it is suitable for advanced renal cell carcinoma ( a discovery of cancer cells in the renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer and non-small cell lung cancer (NSCLC) treatment.
Minnesota Rochester, Mayo Clinical Research Clinical Research Center researches show that pazopanib (trade name Votrient) can effectively cure thyroid cancer,and can make half of the patients tumor volume reduced, compared to the commonly used drugs ,it is more prolonged stable ,and can be maintained for a considerable period of treatment, the drug has the highest response rate in treatment of thyroid cancer so far.
The US Food and Drug Administration (FDA) approved on October 19, 2009 that pazopanib (trade name Votrient) is listed ,the sixth approved drug treatment of kidney cancer since 2005. In 2009, approximately 49,000 patients were diagnosed with renal cell carcinoma, 11,000 patients died of the disease.
June 15, 2010, pazopanib, EU conditionally approved it for advanced renal cell cancer and first-line treatment in patients with previously received cytokine therapy. Once the European Commits to give final marketing authorization for this drug, GlaxoSmithKline will have exclusive marketing rights pazopanib for ten years.

The efficacy of the treatment of advanced renal cell carcinoma

In order to investigate the efficacy of molecule targeting drug tyrosine kinase inhibitor pazopanib which inhibist the angiogenesis in patients with advanced renal cell carcinoma, People's Liberation Army General Hospital, in June 2006 to May 2007, the participation of pazopanib in patients with advanced renal cell carcinoma randomized clinical drug trials of outpatient 14 cases, were divided into pazopanib group (n = 10) and placebo group ( 4 cases), were treated with pazopanib 800mg/d and placebo after 12 weeks of treatment duration, according to the results of CT scan before and after medication , efficacy was determined .
The results showed that the reduced average ratios of measurable disease focus of pazopanib and placebo patients were 27.6%,-2.8% (P <O.05); the disease control rate of pazopanib and placebo groups were 100% and 25%, respectively. Conclusions confirmed that molecule targeting drug tyrosine kinase inhibitor pazopanib which inhibist the angiogenesis can have a significant therapeutic effect and high security on metastatic renal cell carcinoma in a short period of time.
A clinical trail study phase I showed that compared with placebo, pazopanib can reduce the risk of death and tumor progression by 54%. Overall,in the product group of patients ,disease progression-free survival (PFS) mean survival time was 9.2 months ,in the placebo group was 4.2 months. In previously treated patients who had not received in this product group average survival time was 11.1 months in the placebo group was 2.8 months; previously received cytokine therapy patients, pazopanib group survived an average of 7.4 months, the placebo group was 4.2 months.
The above information is edited by the chemicalbook of Tian Ye.

Adverse reactions

Diarrhea, hypertension, hair color change, nausea, loss of appetite, vomiting, fatigue, weakness, headache, abdominal pain and so on.
Cause serious liver problems, so health care workers should take blood tests to monitor liver function before using the drug in patients and during treatment of patients.
Hazardous to the fetus,people during pregnancy are forbid using this drug.
Pazopanib can also lead to arrhythmias, during treatment patients should have regular electrocardiogram measuring heart rate, and regular blood tests to monitor electrolytes since an electrolyte imbalance will also play a role in arrhythmia.

Description

Pazopanib is a multi-kinase inhibitor that inhibits the VEGF receptors VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively, in a cell-free enzyme assay). It also inhibits PDGFRα, PDGFRβ, and c-Kit (IC50s = 71, 84, and 74 nM, respectively, in a cell-free enzyme assay) as well as additional receptor tyrosine kinases. Pazopanib inhibits upregulation of the surface adhesion proteins ICAM-1 and VCAM-1 induced by VEGF in multiple myeloma cells cocultured with human umbilical vein endothelial cells (HUVECs) and decreases multiple myeloma cell adhesion to HUVECs. It also inhibits proliferation of multiple myeloma cells cocultured with HUVECs. Pazopanib (30 and 100 mg/kg) reduces tumor growth, induces apoptosis, decreases angiogenesis, and increases survival in a multiple myeloma mouse xenograft model. Formulations containing pazopanib have been used in the treatment of cancer.

Chemical Properties

Off-White Solid

Characteristics

Class: receptor tyrosine kinase
Treatment: RCC, STS
Oral bioavailability = 14–39%
Elimination half-life = 31 h
Protein binding > 99.9%

Uses

An oral angiogenesis inhibitor targeting VEGFR and PDGFR.

Uses

Pazopanib Hydrochloride (GW786034, Votrient, Armala) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.

Uses

Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR-α/β, and c-Kit.

Uses

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.

Definition

ChEBI: A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.

Clinical Use

Tyrosine kinase inhibitor:
Treatment of metastatic renal cell carcinoma and soft tissue sarcoma

target

VEGFR1

Drug interactions

Potentially hazardous interactions with other drugs
Antibacterials: avoid with clarithromycin, rifampicin and telithromycin.
Antifungals: avoid with itraconazole, ketoconazole and voriconazole.
Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
Antivirals: avoid with atazanavir, boceprevir, indinavir, ritonavir and saquinavir.
Grapefruit juice: avoid concomitant administration.
Avoid concomitant use with other inhibitors or inducers of CYP3A4. Dose alterations may be required.

Metabolism

Metabolism primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8. The four principle pazopanib metabolites account for only 6% of the exposure in plasma. One of these metabolites inhibits the proliferation of VEGF-stimulated human umbilical vein endothelial cells with a similar potency to that of pazopanib, the others are 10- to 20-fold less active.
Therefore, activity of pazopanib is mainly dependent on parent pazopanib exposure.
Elimination is mostly via the faeces.

Pazopanib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Pazopanib Suppliers

Bangladesh 1 Canada 2 China 354 Czech Republic 1 Germany 2 India 26 Poland 1 United Kingdom 2 United States 34 Global 423
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
HBCChem, Inc.
Tel
+1-510-219-6317
Fax
+1-650-486-1361
Email
sales@hbcchem.com
Country
United States
ProdList
10648
Advantage
60
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32165
Advantage
58
Alfa Chemistry
Tel
Fax
1-516-927-0118
Email
Info@alfa-chemistry.com
Country
United States
ProdList
24072
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Cckinase, Inc.
Tel
+1 (732)236-3202
Email
sales@cckinase.com
Country
United States
ProdList
2738
Advantage
58
BOC Sciences
Tel
+1-631-485-4226
Fax
1-631-614-7828
Email
inquiry@bocsci.com
Country
United States
ProdList
19553
Advantage
58
Alchem Pharmtech,Inc.
Tel
8485655694
Email
sales@alchempharmtech.com
Country
United States
ProdList
63687
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
TargetMol Chemicals Inc.
Tel
+8613564774135
Email
zijue.cai@tsbiochem.com
Country
United States
ProdList
19885
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38632
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
LC Laboratories
Tel
--
Fax
--
Email
custserv@lclabs.com
Country
United States
ProdList
503
Advantage
50
Molcan Corporation
Tel
--
Fax
--
Email
info@molcan.com
Country
United States
ProdList
686
Advantage
60
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
Selleck Chemicals LLC
Tel
--
Fax
--
Email
sales@selleckchem.com
Country
United States
ProdList
1848
Advantage
58
RTM Pharmaceuticals, L.L.C.
Tel
--
Fax
--
Email
jlevi@rtmpharma.com
Country
United States
ProdList
41
Advantage
58
Natland International Corporation
Tel
--
Fax
--
Email
info@natland.com
Country
United States
ProdList
156
Advantage
50
ACIC Fine Chemicals Inc.
Tel
--
Fax
--
Email
sales@acic.com
Country
United States
ProdList
492
Advantage
48
Creative Enzymes
Tel
--
Fax
--
Email
info@creative-enzymes.com
Country
United States
ProdList
6057
Advantage
58
Combi-Blocks Inc.
Tel
--
Fax
--
Email
sales@combi-blocks.com
Country
United States
ProdList
6618
Advantage
69
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
ChemieTek
Tel
--
Fax
--
Email
info@chemietek.com
Country
United States
ProdList
219
Advantage
50
Ivy Fine Chemicals
Tel
--
Fax
--
Email
sales@ivychem.com
Country
United States
ProdList
6493
Advantage
58
LKT Laboratories, Inc.
Tel
--
Fax
--
Email
info@lktlabs.com
Country
United States
ProdList
2164
Advantage
64
AK Scientific, Inc.
Tel
--
Fax
--
Email
sales@aksci.com
Country
United States
ProdList
6347
Advantage
65
Tinib-Tools
Tel
--
Fax
--
Country
United States
ProdList
164
Advantage
0
Natland International Corporation
Tel
--
Fax
--
Country
United States
ProdList
314
Advantage
42
Selleck Chemicals LLC
Tel
--
Fax
--
Email
info@selleckchem.com
Country
United States
ProdList
824
Advantage
60
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
Exlcusive Chemistry Ltd
Tel
--
Fax
--
Country
United States
ProdList
446
Advantage
71
More
Less

View Lastest Price from Pazopanib manufacturers

Nanjing Fred Technology Co., Ltd
Product
Pazopanib 444731-52-6
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99%，single impurity＜0.1
Supply Ability
1 ton
Release date
2023-12-19
shandong perfect biotechnology co.ltd
Product
Pazopanib 444731-52-6
Price
US $0.00/g
Min. Order
1g
Purity
98% HPLC
Supply Ability
1KG
Release date
2023-08-02
Hebei Yanxi Chemical Co., Ltd.
Product
Pazopanib 444731-52-6
Price
US $40.00/kg
Min. Order
1kg
Purity
0.99
Supply Ability
10 tons
Release date
2023-09-18

444731-52-6, PazopanibRelated Search:

3-Methyl-6-nitroindazole N,N-Dimethylformamide p-Toluenesulfonamide Dacthal Sulfanilamide 3-Aminobenzenesulfonamide Xylene Dimethyl sulfoxide Dimethyl sulfate Dimethyl phthalate Dimethyl fumarate Benzenesulfonamide Dimethyl carbonate N,N-Dimethyl-1,4-phenylenediamine ETHANE Dimethyl ether N-(2-chloropyriMidin-4-yl)-N,2,3-triMethyl-2H-indazol-6-aMine N-(2-Chloropyrimidin-4-YL)-2,3-dimethyl-2H-indazol-6-amine

  • Pazopanib for research
  • 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
  • Pazopanib
  • CS-1857
  • Pazopanib (free base) (GW786034, Votrient)
  • Pazopanib(GW786034)
  • 5-(4-((2,3-diMethyl-3,3a-dihydro-2H-indazol-6-yl)(Methyl)aMino)pyriMidin-2-ylaMino)-2-MethylbenzenesulfonaMide
  • 5-[(4-{[(2,3-diMethyl-2H-indazol-6-yl)Methyl]aMino}pyriMidin-2-yl)aMino]-2-Methylbenzene-1-sulfonaMide
  • 5-({4-[(2,3-diMethyl-2H-indazol-6-yl)(Methyl)aMino]pyriMidin-2-yl}aMino)-2-MethylbenzenesulfonaMide 5-(4-(N-(2,3-diMethyl-2H-indazole-6-yl)- N-MethylaMino)pyriMidine-2-ylaMino)-2-MethylbenzenesulfonaMide
  • GW786034; VOTRIENT
  • Votrient
  • 5-[[4-[(2,3-DiMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-benzenesulfonaMide
  • BenzenesulfonaMide, 5-[[4-[(2,3-diMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-
  • Pazopanib base
  • Votrient(pazopanib)
  • 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Pazopanib
  • Pazopanib 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
  • Pazopanib, >=99%
  • 5-[4-[(2,3-Dimethyl-2H-indazol-6-yl)-methyl-amino]-pyrimidin-2-ylamino]-2-methyl-benzenesulfon
  • Pazopanib USP/EP/BP
  • Pazopanibr
  • 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
  • PazopanibQ: What is Pazopanib Q: What is the CAS Number of Pazopanib Q: What is the storage condition of Pazopanib Q: What are the applications of Pazopanib
  • Palmer azole panitan
  • Pezopanil Hcl
  • 444731-52-6
  • C21H23N7O2S
  • API
  • API
  • Inhibitors
  • HFC80010
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • 444731-52-6